William Duke Sells 20,964 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) CFO William Duke sold 20,964 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total value of $33,123.12. Following the transaction, the chief financial officer directly owned 107,717 shares in the company, valued at approximately $170,192.86. This represents a 16.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Invivyd Stock Performance

Shares of IVVD stock opened at $1.61 on Friday. The company has a market capitalization of $375.32 million, a price-to-earnings ratio of -3.43 and a beta of 0.60. The stock’s 50 day simple moving average is $2.17 and its 200 day simple moving average is $1.75. Invivyd, Inc. has a twelve month low of $0.46 and a twelve month high of $3.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IVVD. Courier Capital LLC bought a new stake in shares of Invivyd in the fourth quarter valued at about $25,000. Bronte Capital Management Pty Ltd. acquired a new position in Invivyd in the 4th quarter valued at approximately $27,000. DRW Securities LLC acquired a new position in Invivyd in the 4th quarter valued at approximately $27,000. ProShare Advisors LLC bought a new stake in shares of Invivyd in the 4th quarter worth approximately $30,000. Finally, State of Wyoming acquired a new stake in shares of Invivyd during the 4th quarter worth approximately $30,000. Institutional investors own 70.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. HC Wainwright upped their price target on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. Zacks Research raised Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Finally, D. Boral Capital restated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.